Wells Fargo & Company Has Lowered Expectations for Tandem Diabetes Care (NASDAQ:TNDM) Stock Price

Key Points

• Wells Fargo cut its price target on Tandem Diabetes Care from $27 to $25 but maintained an “overweight” rating; the new target implies 56% upside from the current share price.
• Analyst views are mixed: MarketBeat reports an average “Hold” rating and a consensus price target of $27.08, with 12 analysts rating the stock Hold and one rating it Sell.
• Tandem’s latest quarter beat expectations: revenue was $283.7 million, up 13.8% year over year, and its loss of $0.10 per share was narrower than forecast. The stock was reported down 11%.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) had its price objective decreased by equities research analysts at Wells Fargo & Company from $27.00 to $25.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the medical device company's stock. Wells Fargo & Company's price objective suggests a potential upside of 56.13% from the company's current price.

Several other brokerages also recently commented on TNDM. Weiss Ratings restated a "sell (e+)" rating on shares of Tandem Diabetes Care in a research report on Tuesday, September 8th. William Blair assumed coverage on shares of Tandem Diabetes Care in a research report on Friday, August 21st. They issued an "outperform" rating for the company. Truist Financial decreased their price target on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, September 24th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $26.00 price objective (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. Finally, Citigroup dropped their price objective on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $27.08.

Tandem Diabetes Care Stock Down 11.0%

TNDM stock opened at $16.01 on Friday. Tandem Diabetes Care has a 12 month low of $12.26 and a 12 month high of $29.65. The firm has a market cap of $1.11 billion, a PE ratio of -17.55 and a beta of 1.59. The firm has a 50 day simple moving average of $17.74 and a 200 day simple moving average of $18.90. The company has a debt-to-equity ratio of 4.62, a current ratio of 3.18 and a quick ratio of 2.65.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.15. The firm had revenue of $283.69 million during the quarter, compared to analysts' expectations of $265.85 million. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The firm's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.31) earnings per share. Equities research analysts forecast that Tandem Diabetes Care will post -0.66 earnings per share for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In other news, Director Christopher J. Twomey sold 1,700 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of large investors have recently bought and sold shares of TNDM. Maryland State Retirement & Pension System bought a new position in shares of Tandem Diabetes Care in the third quarter valued at approximately $249,000. Fulcrum Asset Management LLP boosted its holdings in shares of Tandem Diabetes Care by 1,463.6% during the 3rd quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company's stock worth $73,000 after buying an additional 4,098 shares during the period. Provenance Wealth Advisors LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth $158,000. Summit Global Investments boosted its holdings in shares of Tandem Diabetes Care by 13.9% during the 3rd quarter. Summit Global Investments now owns 24,753 shares of the medical device company's stock worth $404,000 after buying an additional 3,017 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in Tandem Diabetes Care by 31.3% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,400 shares of the medical device company's stock valued at $561,000 after buying an additional 8,200 shares during the last quarter.

Trending Headlines about Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q3 revenue was $283.7 million, up 13.8% year over year and above analyst estimates of $265.9 million. The company’s loss of $0.10 per share was also narrower than expected. Tandem Q3 2026 financial results
• Positive Sentiment: Gross margin improved to 57%, up 2.7 percentage points from a year earlier. Tandem also reported about 33,000 pump shipments, supporting evidence of business growth. Tandem Q3 2026 financial results
• Positive Sentiment: Management forecast 2026 sales of $1.065 billion to $1.085 billion, giving investors a full-year revenue range to assess against the company’s growth trajectory. 2026 sales outlook and CEO transition
• Neutral Sentiment: Tandem named Jeannette Bankes as president and CEO as John Sheridan plans to retire at the end of 2026. Naming a successor provides advance notice, though investors may watch for details on strategic continuity during the transition. Tandem names Jeannette Bankes CEO

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem's product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.